摘要
目的：比较艾塞那肽联合甘精胰岛素和门冬胰岛素联合甘精胰岛素在治疗2型糖尿病中的疗效。方法：将102例肥胖2型糖尿病患者随机分为艾塞那肽联合甘精胰岛素组和门冬胰岛素联合甘精胰岛素组，治疗12周后，观察患者血糖、糖化血红蛋白（HbAlC）、体重指数（BMI）、血脂、肝功、肾功等差异。结果：治疗12周后艾塞那肽组和门冬胰岛素组均能明显降低空腹血糖、餐后2h血糖、糖化血红蛋白（P〈0．01），下降水平两组无显著差异（P〉0．05）；艾塞那肽组可显著降低BMI、降低甘油三酯、升高高密度脂蛋白（P〈0．01），门冬胰岛素组无显著差异，两者有统计学意义（P〈0．05）。结论：艾塞那肽组与门冬胰岛素组均能很好地降低空腹血糖、餐后血糖、HbAlC，而前者更显示出显著的降低血糖和减轻体重的双重作用，有望成为肥胖糖尿病患者的新选择。
OBJECTIVE： To compare the clinical effect between exenatide combined joint insulin glargine and insulin aspart com- bined joint glargine in patients with type 2 Diabetes Mellitus. METHODS： Sixty patients with type 2 diabetes were randomly divided into exenatide combined insulin gIargine group and insulin aspart combined glargine group. After 12 weeks blood glucose, glycated he- moglobin, body mass index, blood lipid, liver function, renal function and other differences were observed. RESULTS： In both groups blood glucose, postprandial 2h plasma glucose and glycolated hemoglobin （HbAIC） （P 〈 0. 01 ） were significantly reduced. There was no differences in both groups （P 〉 O. 05）. In exenatide group body mass index （BMI） and triglycerides Were reduced significantly and high density lipoprotein was increased （ P 〈 0. 01 ） and there was no significant difference between the two groups, and there was statistically significant （ P 〈 0. 05 ）. CONCLUSION ： Both exenatide group and aspart group have a strong effect on lowering the fasting blood glucose, postprandial blood glucose and HbAl C. But the former also shows a significant reduction in blood sugar and body weight, which is expected to become the new choice for obese patients with diabetes.
出处
《国际老年医学杂志》
2012年第1期6-8,共3页
International Journal of Geriatrics
